Once-Daily Adcirca® (tadalafil) for the Treatment of PAH

Power to move*

Adcirca — the only once-daily phosphodiesterase-5 (PDE-5) inhibitor for Pulmonary Arterial Hypertension (PAH) — WHO Group 1 — that improves your ability to exercise and may delay worsening of your disease. Adcirca is FDA approved across all functional classes of PAH.

Simple to start

Adcirca (pronounced Ad-sur-kuh) is taken as 2 tablets only once a day and is widely available in pharmacies nationwide.

Adcirca is designed to make PAH treatment simple with its:

  • Once-daily dosing
  • Ability to be taken with or without food
  • Availability at both retail and specialty pharmacies

Indication: Adcirca is a prescription medication used to treat pulmonary arterial hypertension (WHO Group 1) to improve exercise ability.

Safety: The most common side effects with Adcirca include headache, muscle pain, getting red or hot in the face (flushing), nausea, pain (in the arms, legs, or back), upset stomach, and stuffy or congested nose.

*The improvement in exercise ability, as measured by 6-minute walk distance, was apparent at 8 weeks of treatment in the pivotal clinical trial for Adcirca.

Adcirca® (tadalafil) Tablets

Indication

ADCIRCA is a prescription medication used to treat pulmonary arterial hypertension (WHO Group 1) to improve exercise ability.

Important Safety Information

You should discuss all of your medical conditions and all medications with your doctor before starting ADCIRCA.

Do not take ADCIRCA if you take any medications that contain nitrates (often used for chest pain), as the combination could cause a sudden, unsafe drop in blood pressure. If you experience chest pain after taking ADCIRCA, contact your doctor.

ADCIRCA is a type of medication called a PDE-5 inhibitor. ADCIRCA contains the same ingredient (tadalafil) as CIALIS, which is used to treat erectile dysfunction (impotence). If you are taking ADCIRCA, do not take CIALIS or other PDE-5 inhibitors. Also do not take ADCIRCA if you are allergic to tadalafil or any other ingredient in ADCIRCA.

PDE-5 inhibitors can cause blood vessels to widen, which may result in a decrease in blood pressure. If you have heart disease or any problems with low blood pressure, tell your doctor before taking ADCIRCA, as these conditions may be affected by the action of ADCIRCA. If you have ever had blockage in the veins of your lungs, known as pulmonary veno-occlusive disease (PVOD), ADCIRCA is not recommended for you.

Do not take ADCIRCA if you are taking rifampin (an antibiotic for certain bacterial infections), or antifungal medications, such as ketoconazole and itraconazole. If you require treatment with both ADCIRCA and ritonavir (Norvir) at the same time, your dose of ADCIRCA will need to be adjusted. Taking ADCIRCA with alcohol, or blood pressure medications, such as alpha-blockers, may lower blood pressure and cause hypotension (fainting). Inform your doctor if you have kidney or liver problems before taking ADCIRCA.

In rare cases, men taking PDE-5 inhibitors (including tadalafil) for erectile dysfunction reported side effects such as a sudden decrease or loss of vision or hearing, or an erection lasting more than four hours. If you experience any of these side effects, seek medical attention right away.

The most common side effects of ADCIRCA are headache, muscle pain, nasal swelling, flushing, respiratory tract infection, extremity pain, nausea, back pain, upset stomach and nasal congestion.

Download the full Prescribing Information and Patient Information or call 1-800-545-5979.

Close Window

Leaving Adcirca.com

You have just clicked on a link that will take you outside the Adcirca website. United Therapeutics Corporation does not monitor, does not imply any endorsement, and is not responsible for the content on outside websites.


Click "OK" to proceed to this third-party website or "CANCEL" to return to Adcirca.com.


Close WindowClose Window
Close Window

Leaving Adcirca.com and going to the United Therapeutics Corporation website

You have just clicked on a link that will take you to the United Therapeutics Corporation website (Unither.com), which has information about Adcirca, as well as other medications.


Click "OK" to proceed to the Unither.com website or "CANCEL" to return to Adcirca.com.


Close WindowClose Window
Close Window

Thank You for Registering!

If you would like to learn more about United Therapeutics Corporation, visit www.unither.com.


Close Window

Duplicate e-mail

The database has detected that you've already registered with this e-mail address. You do not need to register for updates again. Thank you for your interest in Adcirca!


Close Window

Functional Classifications of PAH

Adcirca is FDA approved for all functional classes of WHO Group 1 PAH and, depending on your specific treatment plan, can be taken as a mono-therapy or combination therapy with bosentan. However, this is something that you should discuss with your doctor to fully evaluate your treatment options and potential risk of interactions with any medications you are taking.

Classification was created by the New York Heart Association (NYHA) to measure the degree of disease severity in patients with PAH. The World Health Organization (WHO) developed a similar functional class system that is also commonly used in assessing patients with PAH.


Close Window

Submit Your Story

If you would like to share your experiences using Adcirca® (tadalafil), we'd love to hear from you! Just fill in the information about yourself, upload your picture, and type or paste your story in the space below, and click "SHARE."

Please do not use this form to report an Adverse Event you have experienced while taking Adcirca. All Adcirca adverse events should be reported by calling your healthcare provider or to us by calling 1-800-545-5979.

Note: Your story will be posted on Adcirca.com only if it is deemed appropriate. Not all stories submitted will be posted.

All fields are required.

* First Name:

* Last Name:

* Gender:

* Email Address:

* Confirm Email Address:

* Zip Code:

* Are you on Adcirca?

23,000 character max.

Upload a photo of yourself to share with your story: You can upload JPG, GIF, or PNG files.   

The file size limit is 5 MB. If your upload does not work, try uploading a smaller picture.

I certify that I have the right to distribute this image and that United Therapeutics Corporation has the right to post it on Adcirca.com.

By clicking the SHARE button, I agree that United Therapeutics Corporation or its representatives may contact me regarding the content of my submission or other services offered for patients taking Adcirca. Furthermore, I grant United Therapeutics Corporation the right to edit my story as appropriate to comply with the requirements for information posted on Adcirca.com. I also agree to United Therapeutics Corporation’s Privacy Policy. I understand that my story will be posted on Adcirca.com only if it is deemed appropriate. Not all stories submitted will be posted. I hereby grant United Therapeutics Corporation an unrestricted, royalty-free, irrevocable license to use, reproduce, display, perform, modify, transmit, and distribute my ideas, information, concepts, know-how, techniques, or materials I transmit through this website, in any form, and agree that United Therapeutics Corporation is free to use them for any purpose.

As a user of this website, you are responsible for your own communications and the consequences of posting them. Therefore, do not do any of the following things: transmit to us material that is copyrighted, unless you are the copyright owner or have the permission of the copyright owner to post it; send material that reveals trade secrets, unless you own them or have the permission of the owner; send material that infringes on any other intellectual property rights of others or on the privacy or publicity rights of others; send material that is obscene, defamatory, threatening, harassing, abusive, hateful, or embarrassing to another user or any other person or entity; send sexually-explicit images; send advertisements or solicitations of business; send chain letters or descriptions of or invitations to participate in pyramid schemes; or impersonate another person. If the company learns or suspects that you may have posted material in violation of these rules, it will remove that material pending further investigation.

Close Window

Thank You for Sharing Your Story!

Your story will now be considered for posting on Adcirca.com. Please note that not all submitted stories will be posted. Thanks for your enthusiasm and support!


Close Window

Electronic Reprint System
Mobile™ ePrint

Hello,

Welcome to the electronic reprint system. Your Mobile™ ePrint is ready for download.

We recommend that you “Save” the file to your desktop for portability.

*** IMPORTANT NOTICE ***
This Mobile™ ePrint is ONLY supported on the PC platform. Mac users please click here for support.

To save your ePrint – Please follow these steps:

Step 1. To download the file, click on the Download File link provided below.

Step 2. To save the file to your desktop, click the “Save” button.

Step 3. Locate the file on your desktop and double click to open.

Download File - LWW_161918_CP.exe

How do I launch my Mobile™ ePrint for the first time?

Simply click on the “Download File” link that is embedded in this email. You will be prompted to either “Run” or “Save” the ePrint file. We recommend you save the ePrint file to a location on your computer where you can locate and activate it at a later time. To open the saved ePrint file simply double-click on the file icon you saved to your computer. You must be connected to the Internet the first time you open your ePrint. This one-time Internet connection allows your ePrint to validate itself.

Click here for more information.

Please email us at requestinfo@tsp.sheridan.com for any ePrint support questions.

Thank you for your order!


Close Window

Coming soon! Register for Updates and we'll send you an email to let you know when we add fresh content to the site.

Close Window

Coming soon! Register for Updates and we'll send you an email to let you know when we add fresh content to the site.